D iverse catastrophic illnesses, ranging from falciparum malaria to acute pancreatitis, often culminate in a critical disruption of normal vascular functions, resulting in tissue edema, poor gas exchange, and shock. Sepsis, the host response to unchecked infection, is both a model example of this phenomenon and, itself, a highly prevalent disorder whose associated mortality makes it a major public health burden (1, 2) .
Secreted inflammatory molecules that act on vascular endothelium, such as tumor necrosis factor-α, bradykinin, and thrombin, induce vascular leakage and inflammation (3) . Yet, efforts to block these molecules have shown no demonstrable benefit in randomized clinical trials. Numerous explanations have been proposed for this failure to translate (4, 5) . One intriguing possibility is that no previous intervention has specifically targeted the host vasculature in human sepsis, where the lethality-inducing manifestations appear to occur (6, 7) .
The Tie-2 receptor is expressed and activated throughout the quiescent adult endothelium (8) where it promotes micro vascular barrier function and antiinflammation (9) (10) (11) . Angiopoietin-2 (Angpt-2) is a secreted protein stored in endothelial cells and released upon inflammatory stimulation that directly antagonizes the Tie-2 ligand, Angpt-1 (12) (13) (14) . We and others have reported that circulating Angpt-2 is elevated in humans with severe sepsis (15) (16) (17) (18) (19) (20) . However, evidence for a deleterious action of Angpt-2 in sepsis has been lacking. Recently, even the correlation of early Angpt-2 concentrations with adverse outcomes in sepsis has been questioned (18) . Resolution in this area is sorely needed, given the ongoing development of antibody-based Angpt-2 inhibitors and the recent negative findings for the only targeted sepsis therapeutic, drotrecogin alpha (21) .
To study these questions, we used genetically manipulated mice, a model of septic Objective: In sepsis, quiescent blood vessels become leaky and inflamed by mechanisms that are incompletely understood. We hypothesized that angiopoietin-2, a partial antagonist of the endothelium-stabilizing receptor Tie-2 secreted by endothelium, contributes to adverse outcomes in this disease.
Design: Laboratory and animal research. Settings: research laboratories and emergency Department of Beth Israel Deaconess Medical Center, Boston, MA.
Subjects: Angiopoietin-2 heterozygous mice, emergency department patients.
Measurements and Main Results: Mice with one functional angiopoietin-2 allele developed milder kidney and lung injury, less tissue inflammation, and less vascular leakage compared to wildtype counterparts. Heterozygotes experienced >40% absolute survival advantage following two different models of sepsis (p = .004 and .018). In human subjects presenting to our emergency department with suspected infection (n = 270 combined), circulating angiopoietin-2 was markedly elevated within the first hour of clinical care. First-hour angiopoietin-2 concentrations were proportional to current disease severity (p < .0001), rose further over time in eventual nonsurvivors (p < .0001), and predicted the future occurrence of shock (p < .0001) or death (p < .0001) in the original cohort and an independent validation group. Finally, septic human serum disrupted the barrier function of microvascular endothelial cells, an effect fully neutralized by an angiopoietin-2 monoclonal antibody.
Conclusions: We conclude that angiopoietin-2 induction precedes and contributes to the adverse outcomes in sepsis, opening a new avenue for therapeutic investigation. ( For information regarding this article, E-mail: sparikh1@bidmc.harvard.edu humoral injury to microvascular endothelium, and two human cohorts composed of subjects with suspected infection captured at the time of hospital presentation, well before admission to critical care units.
METHODS

Mouse studies
In Institutional Animal Care and Use Committee-approved studies, we used 8-wkold male ANGPT-2 heterozygous mice on a 129Sv/C57BL6 mixed background and their wild-type littermates (gift of S. Wiegand, Regeneron Pharmaceuticals, Tarrytown, NY). Endotoxemia was induced via IP administration of 15 mg/kg body weight lipopolysaccharide from Escherichia coli, serotype O111:B4 (Sigma-Aldrich, St. Louis, MO) dissolved in 10 mL/kg sterile phosphate buffered saline. Cecal ligation and puncture (CLP) was performed by a single operator (S.D.) blinded to genotype, as previously described (23) . In brief, under sterile conditions with inhaled isoflurane (1-3% in medical air), a midline laparotomy was placed. Sterile Q-tips were used to deliver the cecum, which was ligated at the antimesenteric border. A single 21-gauge needle puncture was made, through which 1 mm of stool gently extruded. Abdominal contents were replaced, and a two-layered closure was performed. Laparotomy with cecal mobilization served as sham surgery. Tissues were harvested 24 hrs after CLP or sham surgery. Survival was followed over the course of 120 hrs.
Confocal Fluorescent Immunohisto chemistry. Air-dried paraformaldehyde-lysine-periodate-fixed cryosections from lungs and kidneys were blocked for 60 mins in 10% donkey serum, incubated with primary antibodies (CD11b 1:500 [BD Biosciences, San Jose, CA], and vascular cell adhesion molecule-1 (VCAM-1) 1:500 [AbD Serotec, Oxford, UK]) overnight at 4°C, followed by fluorescence-conjugated affinity-purified secondary antibody labeling (60 mins, 1:500; Jackson ImmunoResearch, West Grove, PA), and mounted with ProLong Gold/4,6-diamidino-2phenylindole (Life Technologies, Grand Island, NY). All images were taken by a Zeiss LSM510 META (Zeiss Microscopy GmbH, Jena, Germany) confocal system at ×63 magnification. Of note, all images were obtained with the same laser power, gain, and offset conditions. Twenty-four fields of three serial tissue sections (3 × 8 images) per animal were obtained for later planimetric VCAM-1 or CD11b semiquantification using a single threshold value for all images (Photoshop, Adobe, version 8.0).
Assessment of Kidney Injury. Kidney function was measured via serum creatinine and blood urea nitrogen using the i-STAT1 handheld clinical analyzer (Abbott, Princeton, NJ).
Assessment of Lung Permeability by Bronchoalveolar Lavage. Twenty-four hours after model induction, mice were lightly anesthetized with isoflurane in medical air; the neck was carefully dissected to expose the trachea. Transverse incision of the trachea inferior to the thyroid cartilage enabled placement of a soft catheter into the airway, which was then connected to a 1-mL syringe loaded with phosphate buffered saline. Lavage was performed with gentle aspiration. Protein was measured by bicinchoninic acid assay.
cell culture Models
Passage 5-6 dermal human microvascular endothelial cells (Lonza, Basel, Switzerland) were cultured in endothelial cell basal medium-2 media (Lonza) supplemented with 5% fetal bovine serum and growth factors according to the manufacturer's instructions at 37°C and 5% CO 2 . Human microvascular endothelial cells were grown to confluence on glass coverslips coated with collagen type I. After human microvascular endothelial cells were starved for 2 hrs in endothelial cell basal medium-2 containing 1% fetal bovine serum, the cells were either treated with 1 μg/mL IgG control Ab or a monoclonal anti-human Angpt-2 Ab (R&D Systems, Rochester, MN) and simultaneously challenged with 5% human septic serum. To do this, endothelial cell basal medium-2 was supplemented not with 5% fetal bovine serum, but with 5% 0.22-μm filtered human serum from n = 5 patients with septic shock whose Angpt-2 ≥20 ng/mL and control serum was from n = 5 noninfected emergency department (ED) control subjects in cohort 1 whose Angpt-2 ≤1 ng/mL.
Confocal Fluorescent Immunocytochemistry. Thirty minutes after mediator treatment, cells were fixed for 10 mins in 2.5% paraformaldehyde and permeabilized for 5 mins in 0.2% Triton X-100 in phosphate buffered saline. Cells were blocked overnight at 4°C with a blocking buffer (1% bovine serum albumin, Triton, and sodium azide), then incubated for 12 hrs with primary antibody (vascular endothelial-cadherin; BD Bioscience, San Diego, CA), serial washes in phosphate buffered saline, then 60 mins incubation with secondary Alexaantibody and phalloidin. The coverslips were mounted by ProLong Gold/4,6-diamidino-2phenylindole. All images were taken by a Zeiss LSM510 META confocal system at ×63 magnification. Of note, all images were obtained with the same laser power, gain, and offset conditions.
clinical study design, definitions, and data collection
An institutional review board-approved prospective cohort study of a convenience sample enrolled 185 adult patients (aged ≥18 yrs) presenting to the ED with suspected infection whose study design has previously been published (24) . Suspected infections was defined as a clinical suspicion of an infectious etiology as assessed by the treating clinician and verified by interviewing the treating clinician if infection was suspected based on the ED work-up, including the results from history, physical examination, laboratory testing, and diagnostic testing. Blood sampling occurred during the proximate portion of the ED work-up, prior to admission to the hospital. We recruited patients (when a research assistant was available) by having them screen and identify eligible patients. The population was sequentially enrolled across the classes of sepsis severity to achieve relatively even distribution of subjects in these subgroups. Thus, during the end of the study, we selected septic shock patients (a more rare occurrence) preferentially over other sepsis severities. A sample of noninfected ED control patients was also assembled by identifying adult ED patients without the evidence of infection during presentation. The study period was between February 2005 and November 2009. A second institutional review board-approved prospective study of 85 adult ED patients was subsequently conducted with identical design to the first between 2007 and 2009. This cohort was used to validate cutoff values generated by receiver operating curve (ROC) analysis of the first cohort for adverse outcomes.
Patients were subsequently defined in both studies as having sepsis, severe sepsis without shock, or septic shock using published American College of Chest Physicians/ Society of Critical Care Medicine definitions (25) . For the assessment of organ dysfunction, we used the Sequential Organ failure Assessment (SOFA) score (26) . Components of demographics, history, comorbid diseases, suspected source of infection, vital sign information, findings of physical examination, and the results of laboratory and radiologic testing were collected. The setting for both studies was Beth Israel Deaconess Medical Center. Written informed consent was obtained.
clinical sample collection and Molecular analysis
All subjects received a study blood draw upon ED presentation. Between January 2007 and January 2009, patients in our first cohort with septic shock (n = 42) received additional blood draws every 24 hrs for the first 3 days. Samples were drawn in EDTA tubes, centrifuged at 2,500 × g at 4°C, and frozen at −80°C within 1 hr of collection. Plasma was assayed for Angpt-1 and Angpt-2 by enzyme-linked immunosorbent assay (R&D Systems) and for soluble E-selectin and soluble intercellular adhesion molecular-1 as part of a multiplex panel using the human cardiovascular-1 panel (Millipore, Billerica, MA). The mean of duplicate measurements was used.
statistical analysis
We used SAS version 9 (SAS Institute, Cary, NC) and SPSS 11.5 (Lead Technologies, Chicago, IL) for statistical analysis. Data are expressed as mean ± sem or as median with interquartile range as appropriate. A twotailed p-value <.05 was considered statistically significant. The normality of distribution of continuous variables was tested using the Kolmogorov-Smirnov test. Circulating Angpt-2 concentration was nonnormally distributed, so nonparametric methods were used. Survival differences of Angpt-2 heterozygous vs. wild-type mice were compared by log-rank test. All other mouse data were analyzed by unpaired two-sided t test. Baseline characteristics of cohort 1 vs. 2 were compared by Mann-Whitney or Fisher's exact test as appropriate. Comparisons across different sepsis severities were performed by Kruskal-Wallis one-way analysis of variance for trends with Dunn's test for multiple comparisons. The correlation of analytes was assessed by a Spearman correlation coefficient. We performed linear regression using a stepwise forward selection technique with adjustment for the strongest covariates. Areas under the ROC were compared using previously reported methodology (27) . ED control patients were designated controls and those with septic shock or those who died were designated as cases, with the null hypothesis that the area under the ROC curve (AUC) equals 0.5.
ethics statement
The mouse studies were in accordance with guidelines set forth by the National Institutes of Health and were approved by the Institutional Animal Care and Use Committee of Beth Israel Deaconess Medical Center. The institutional review board of Beth Israel Deaconess Medical Center approved the clinical studies.
RESULTS
angpt-2 heterozygous Mice have superior survival Following Models of sepsis
No prior study had explored the effect of genetic Angpt-2 depletion in models of the disease, despite evidence that Angpt-2 is induced and Tie-2 is inactivated (28) . As opposed to homozygous null mice (22) , Angpt-2 heterozygous mice develop normally without chylous ascites and exhibit normal fertility. We applied two distinct models of sepsis: CLP and endotoxemia from IP lipopolysaccharides. Angpt-2 heterozygous male mice experienced an absolute survival advantage exceeding 40% compared to wild-type littermates (lipopolysaccharide: 46.6%, p = .004; CLP: 41.7%, p = .018; Fig. 1 ). Measurement of Angpt-2 by quantitative polymerase chain reaction on lung homogenates confirmed that heterozygotes had lower baseline expression and less induction of Angpt-2 following sepsis (Supplemental Fig. 1 , Supplemental Digital Content 1, http:// links.lww.com/CCM/A483).
angpt-2 heterozygous Mice develop less vascular inflammation in the Kidneys and lungs Following experimental sepsis
To test whether Angpt-2 was sensitizing endothelium to the inflammatory sepsis milieu, we stained kidney and lung sections for VCAM-1, an adhesion protein for activated leukocytes. In wild-type animals, CLP enhanced VCAM-1 staining in glomeruli and peritubular capillaries (Fig. 2, A and B) . Angpt-2 heterozygotes displayed less inflammation in both microvascular compartments after CLP. The validity of this technique was confirmed by planimetric quantification of VCAM-1 staining (Supplemental Fig. 2 , Supplemental Digital Content 1, http:// links.lww.com/CCM/A483). Angpt-2 heterozygosity similarly attenuated CLPinduced VCAM-1 staining in lung vessels (Fig. 2C ).
angpt-2 heterozygous Mice develop less cellular inflammation and organ dysfunction Following experimental sepsis
Based on the VCAM-1 results, we tested whether Angpt-2 affects cellular inflammation by staining for the activated leukocyte marker CD11b. Representative results in the lung are shown in Figure 3A . CLPinduced CD11b staining was substantially reduced in Angpt-2 heterozygotes. These results were confirmed quantitatively in lung and kidney sections ( Fig. 3B and C) . We then assessed the extent of injury in these two susceptible organs. CLP-induced protein extravasation into the lung airspaces was reduced in Angpt-2 heterozygotes ( Fig. 3D) . Similarly, sepsis-induced acute kidney injury was also attenuated (Fig. 3E ). To rule out an effect of Angpt-2 on macrocirculatory function during sepsis that would explain distant organ injury, we performed serial echocardiography. CLP suppressed cardiac output and stroke volume in wild-type mice, but these changes were not altered in Angpt-2 heterozygotes (Supplemental Fig. 3 
immune inhibition of angpt-2 attenuates Microendothelial injury induced by humoral sepsis Mediators
We next asked whether immune inhibition of Angpt-2 could prevent the effect of humoral sepsis mediators on the microvascular endothelium by incubating 5% human serum from subjects with septic shock on confluent human microvascular endothelial cells and staining for the junctional protein vascular endothelialcadherin and F-actin. Septic shock serum induced the formation of focal adhesions, actin stress fibers, and multiple paracellular gaps, changes not observed when the experiment was performed with serum from noninfected control subjects (Fig. 4 ) or with serum from subjects whose sepsis has resolved. These structural changes were entirely prevented when cells were simultaneously treated with a monoclonal anti-human Angpt-2 Ab, but not an isotype control IgG.
In Subjects With Suspected Infection, Elevated Circulating Angpt-2 Is Apparent Within the First Hour of Hospitalization
With evidence of the effect of Angpt-2 on endothelial structure and inflammation impacting end-organ function in sepsis, we next studied two cohorts of patients presenting to our ED with suspected infection. The first cohort (n = 185) had a mean age of 57 ± 20 yrs; 52% were male, 77% were Caucasian, and there was a high comorbid burden of diabetes (25%), cancer (19%), and chronic heart failure (12%; Table 1 ). The validation cohort of 85 subjects was older (63 ± 17 yrs; p = .02), had a higher fraction of African American patients (12% vs. 25%; p = .01), bore a similar burden of comorbid illnesses except cancer, and had a higher median Acute Physiology and Chronic Health Evaluation II score (11 vs. 15 ; p = .004; Table 1 ). Anatomical sites of infection were not statistically different between the two cohorts (Supplemental Table 2 , Supplemental Digital Content 1, http://links.lww.com/CCM/A483).
Angpt-2 concentration was measured in enrollees' plasma within the first hour of ED presentation. In the first cohort, median levels of Angpt-2 were progressively higher across worsening levels of disease severity, ranging from 1.78 (0.96-2.31) ng/mL in noninfected ED controls to 6.17 (3.34-12.31 ) ng/mL in individuals with septic shock (Fig. 5A ; p < .0001). This same pattern of progressive Angpt-2 elevation was confirmed in the second cohort-control: 1.23 (0.9-2.3), sepsis: 3.39 (2.1-5.6), severe sepsis: 3.75 (2.5-13.6), and septic shock: 6.25 (3.1-13.0) ng/ mL ( Fig. 5B; p < .0001 ). Angpt-1 showed a trend in the opposite direction, but intergroup differences were not significant (Supplemental Fig. 4 , Supplemental Digital Content 1, http://links.lww.com/CCM/ A483). Subsequent data are presented for the first cohort, unless otherwise specified.
First-hour Angpt-2 Values Correlate With 72-hr Incidence of Severe Sepsis and Angpt-2 Values Progressively Rise in Eventual Nonsurvivors
A series of univariate correlations confirmed that first-hour Angpt-2 was significantly associated with the metabolic marker lactate, the inflammatory molecules soluble intercellular adhesion molecule-1, soluble E-selectin, and interleukin-6, and two different scoring systems for clinical disease severity, SOFA (r = .53, p < .0001) and Acute Physiology and Chronic Health Evaluation II (r = .51, p < .0001; Supplemental Fig. 5 , Supplemental Digital Content 1, http://links.lww. com/CCM/A483). First-hour Angpt-2 was also more elevated in subjects who developed acute kidney injury or acute lung injury within the first 72 hrs (Supplemental Fig. 6 , Supplemental Digital Content 1, http://links.lww.com/CCM/A483; p < .01).
We subdivided the values for Angpt-2 into quartiles to analyze its association with adverse outcomes. The 72-hr Cells were treated for 30 mins with media supplemented with 5% serum from an individual with septic shock (second and third rows); 5% healthy human serum served as a con trol (first row). White arrows point to paracellular gaps in the "septic serum" + IgG group (second row) that were prevented in the septic serum + Angpt-2 Ab group (third row). Staining results are representative for the effects of sera plus isotype control Ab vs. sera plus Angpt-2 Ab from five different subjects with septic shock experiments per condition. Scale bar = 10 μm. incidence of severe sepsis rose steadily as the first-hour Angpt-2 increased ( Fig. 6A ; p = .001). A multivariable-adjusted linear regression model showed that the firsthour Angpt-2 quartile was a significant predictor of the SOFA score (Supplemental Table 3 , Supplemental Digital Content 1, http://links.lww.com/CCM/A483). Serial blood draws over the first 72 hrs of hospitalization from 42 subjects with septic shock showed that eventual nonsurvivors had a higher first-hour Angpt-2 that increased even further over the first 72 hrs, whereas eventual survivors started lower and stayed lower than nonsurvivors ( Fig. 6B ).
First-hour angpt-2 value can classify eventual disease severity
We used ROC analysis on first-hour Angpt-2 values for major clinical outcomes. The AUC showed strong discriminating power for predicting death (AUC = 0.92) and moderate power for predicting severe sepsis or shock within the first 72 hrs (AUC = 0.82 and AUC = 0.73, respectively). Not only did AUCs of Angpt-2 compare favorably against markers of inflammation (Supplemental Table 4 , Supplemental Digital Content 1, http:// links.lww.com/CCM/A483) but also addition of first-hour Angpt-2 (AUC = 0.82) to the SOFA score (AUC = 0.88) increased the AUC (combined AUC = 0.91, p < .01 vs. Angpt-2 alone and p < .05 vs. SOFA alone) for predicting severe sepsis within the first 72 hrs compared to either measurement alone. First-hour Angpt-2 had a higher AUC for severe sepsis and septic shock than first-hour Angpt-2/Angpt-1 ratio, and first-hour Angpt-1 values were uninformative for those outcomes (Supplemental Table 5 , Supplemental Digital Content 1, http://links.lww.com/CCM/ A483).
ROC analyses generated cutoff values of first-hour Angpt-2 that maximized sensitivity and specificity (Supplemental Table 6 , Supplemental Digital Content 1, http://links.lww.com/CCM/A483). For example, of the 97 subjects with firsthour Angpt-2 ≤3.56 ng/mL, only 14 (14.4%) developed septic shock in the first 72 hrs whereas 42 of the 88 sub jects whose value exceeded 3.56 ng/mL (47.7%) developed shock in the first 72 hrs ( Fig. 7A ; p < .0001). Even more strikingly, 0 of 120 subjects with first-hour Angpt-2 values ≤5.1 ng/mL died during their hospitalization, whereas 11 of 65 (16.9%) subjects with values exceeding 5.1 ng/mL suffered in-hospital mortality ( Fig. 7C ; p < .0001). We then applied these independently derived cutoff values to the second cohort and observed nearly identical stratification (Fig. 7, B and D; p = .001 for 72-hr septic shock and p = .0008 for in-hospital mortality).
DISCUSSION
Experimental sepsis is characterized by inactivation of Tie-2 and up-regulation of Angpt-2. In this study, genetic deletion of Angpt-2 conferred an array of protective effects to septic mice, including a robust survival advantage. An Angpt-2 monoclonal antibody prevented septic humoral injury to microvascular endothelium. Finally, in subjects with suspected infection, circulating Angpt-2 was reproducibly elevated at the earliest juncture of medical care, suggesting that an Angpt-2 neutralization strategy would have a reasonable therapeutic time window in the human disease.
Previous data show that Angpt-2 is sufficient to destabilize endothelium, cause vascular leakage, and induce inflammation (15, 29, 30) . The current experiments suggest that it is necessary as well, at least in sepsis. The mechanism by which Angpt-2 influences vascular leakage and inflammation is likely through downstream inhibition of Tie-2 signaling (15, 29, 31) as Tie-2 stimulation by Angpt-1 or an unrelated peptide mitigates both phenomena (32) (33) (34) (35) (36) (37) . In further support of this, acute figure 5. Elevated circulating angiopoietin-2 (Angpt-2) at the first hour of hospitalization. A, Angpt-2 box and whisker blots stratified by initial sepsis syndrome severity in the first (A) and second (B) cohorts in the order of disease severity from low to high: uninfected controls (emergency department [ED] control), sepsis without organ dysfunction (sepsis), sepsis with organ dysfunction but not shock (severe sepsis), and septic shock (septic shock). suppression of Tie-2 induces barrier dysfunction and vascular leakage ( [15] and unpublished observations). Tie-2 defends endothelial barrier function through the stabilization of vascular endothelial-cadherin, a transmembrane protein whose homotypic interactions between neighboring endothelial cells is critical for normal barrier function (35, 38, 39) . The antiinflammatory effects of Tie-2 activation are less well-characterized, but probably no less important in sepsis (11) . In agreement with this concept, prior studies of Angpt-2 knockout mice suggest that this molecule is necessary for the full inflammatory response in nonsepsis settings (40, 41) .
These data may help explain the sustained Tie-2 phosphorylation that has been observed throughout the adult vasculature (8) . Constitutive activation of Tie-2 in mature blood vessels may be necessary for the maintenance of vascular barrier function and anti-inflammation while simultaneously enabling the up-regulation of a single molecule, Angpt-2, to reverse this quiescent state rapidly. Indeed, pre-formed Angpt-2 is localized to the Weibel-Palade bodies of endothelial cells, whose contents are exocytosed following stimulation with several inflammatory mediators (12) . Although speculative, a spring-loaded "inflammation-leak" response driven by endothelial Angpt-2 release would be useful for delivering humoral effectors and innate immune cells to local sites of infections. The vascular changes of sepsis may, therefore, represent the maladaptive effects of globally applying a useful local response to infection.
The present data show that the sickest individuals-those with shock who are destined to die-present for medical care with markedly increased Angpt-2 and that Angpt-2 continues to rise as they clinically deteriorate. In contrast, future survivors of septic shock have less severe initial Angpt-2 elevation and do not progress over time. The clinical data help clarify issues raised by prior studies. First, we found that Angpt-2 is abnormally elevated at relatively low levels of clinical severity (18, 42) . Second, the degree of Angpt-2 elevation during the first hour of clinical care predicts progressively worse outcomes of sepsis, with cutoff levels that perform reproducibly in an independent second cohort. This result contrasts with a smaller intensive care unit-based study in which early circulating Angpt-2 levels in the intensive care unit were not associated with changes in mortality (18) . Finally, no previous study has shown that Angpt-2 is elevated in patients with suspected infection at the onset of medical care in the ED, where early interventions have a proven survival benefit (43) .
Important limitations of the current study should also be noted. First, bias may have been introduced in the clinical portion of this work by convenience sampling or the subjective inclusion criterion of "suspicion of infection." Related to this, the high negative predictive value of Angpt-2 <5.1 ng/mL for ruling out in-hospital mortality may be different in a broader cross-sectional study of ED patients, which is clearly merited. However, we would anticipate that the lower pretest probability of death in such a study would actually enhance the negative predictive value of an Angpt-2 cutoff beyond the ~95% that we have reported. Second, the mortality rate in our samples was lower than typical intensive care unit studies-a side effect of an ED-based study-but this setting also enabled us to explore how Angpt-2 might be used when diagnostic information is limited. Third, the upstream regulators of Angpt-2 and downstream effectors need further elucidation. Is the Angpt-2 mostly derived from endothelial cells and acting in a paracrine fashion, or elaborated by monocytes and acting on monocytes (44, 45) , or made by one cell type, but acting on the other, or some combination? Lastly, given the prior instances in which rodent findings have failed to translate into human advances for sepsis (4) , the only conclusive test of the present hypothesis would be the successful application of Angpt-2 neutralization in critically ill human subjects with sepsis. figure 7. Discriminating power of first-hour angiopoietin-2 (Angpt-2). Cutoff values for discriminating 72-hr occurrence of septic shock and in-hospital mortality were determined by receiver operating characteristic analysis of the first cohort (left column) and then applied to the second cohort (right column). A and B, Application of an Angpt-2 cutoff of 3.56 ng/mL for 72-hr septic shock in the first and second cohorts, respectively. C and D, Application of an Angpt-2 cutoff of 5.1 ng/mL for in-hospital mortality in the first and second cohorts, respectively.
CONCLUSIONS
In summary, this study provides new evidence that Angpt-2 is detrimental in sepsis by jointly considering results from genetically manipulated mice, immunodepletion, and two human disease cohorts. We propose that Angpt-2 neutralization in sepsis may be a promising avenue for future exploration.
